Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 7
1963 4
1964 3
1965 4
1966 2
1967 2
1968 1
1969 3
1970 3
1975 1
1978 1
1992 1
1994 1
1996 2
1997 1
1998 1
2004 4
2005 4
2006 2
2007 4
2008 6
2009 2
2010 3
2011 1
2012 3
2013 3
2014 2
2015 2
2016 1
2018 2
2019 3
2020 2
2021 3
2022 4
2023 6
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Attard G, et al. Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23. Lancet. 2022. PMID: 34953525 Free PMC article.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigators. Attard G, et al. Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1. Lancet Oncol. 2023. PMID: 37142371 Free PMC article.
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, Lall S, Thakali S, Wingate A, Wetterskog D, Sachdeva A, Sydes MR, McPhail N, Sreenivasan T, O'Sullivan JM, Clarke NW, Parmar MKB, Brown LC, James ND, Demichelis F, Attard G; STAMPEDE collaborators. Leone G, et al. JAMA Oncol. 2025 Feb 27;11(4):426-9. doi: 10.1001/jamaoncol.2024.7051. Online ahead of print. JAMA Oncol. 2025. PMID: 40014335
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Cathomas R, et al. Among authors: strebel rt. J Clin Oncol. 2023 Nov 20;41(33):5131-5139. doi: 10.1200/JCO.23.00363. Epub 2023 Aug 17. J Clin Oncol. 2023. PMID: 37590894 Free PMC article. Clinical Trial.
Dynamics of calciphylaxis.
Strebel RF, Wagner BM. Strebel RF, et al. Clin Orthop Relat Res. 1970 Mar-Apr;69:87-100. Clin Orthop Relat Res. 1970. PMID: 5442536 No abstract available.
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
Kaufmann E, Aeppli S, Arnold W, Balermpas P, Beyer J, Bieri U, Cathomas R, de Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann TRW, Hermanns T, Ilaria L, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Reinhardt K, Salati E, Sèbe P, Shelan M, Strebel R, Templeton AJ, Vogl U, Wettstein MS, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser C. Kaufmann E, et al. Among authors: strebel r. World J Urol. 2024 Sep 19;42(1):527. doi: 10.1007/s00345-024-05196-7. World J Urol. 2024. PMID: 39297968 Free PMC article.
Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, Plass K, Ribal MJ, Roobol MJ, Nieboer D, Schouten N, Skolarus TA, Smith EJ, N'Dow J, Mottet N, Briganti A; Pan-European National Urological Society IMAGINE Collaborative (see Supplemental material for group members affiliations):. MacLennan S, et al. Eur Urol. 2023 May;83(5):393-401. doi: 10.1016/j.eururo.2022.12.031. Epub 2023 Jan 11. Eur Urol. 2023. PMID: 36639296 Free article.
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas R; Swiss Group for Clinical Cancer Research (SAKK). Afferi L, et al. Among authors: strebel rt. BJU Int. 2024 Sep;134(3):388-397. doi: 10.1111/bju.16318. Epub 2024 Mar 8. BJU Int. 2024. PMID: 38456541 Clinical Trial.
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW; STAMPEDE investigators. Gillessen S, et al. Lancet Oncol. 2025 Aug;26(8):1018-1030. doi: 10.1016/S1470-2045(25)00231-1. Epub 2025 Jul 7. Lancet Oncol. 2025. PMID: 40639383 Free PMC article. Clinical Trial.
97 results